CytRx Faces Nasdaq Delisting Hearing

genomeweb
360dx

CytRx Faces Nasdaq Delisting Hearing

Apr 28, 2004

NEW YORK, April 28 (GenomeWeb News) - CytRx faces a May 13 hearing before the Nasdaq Qualifications Panel over a possible delisting of the company's common stock from the Nasdaq Small Cap market.

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

People in the News: Christopher Bernard, Chris Emery, Jeffery Henderson, Michelle Griffin
In Brief This Week: NanoString, VolitionRx, Grifols, and More
Diagenode Acquires Epigenetics Firm Nxt-Dx
New Products Posted to GenomeWeb: Helomics, Empirical Bioscience, IncellDx, More
Signature Science Wins $2.3M Government Contract to Develop Forensic Tool
Illumina Prices Senior Notes Offering

The Scan

This Week in Science

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

New Framework Suggested

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

Penguins With Roving Eyes

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Funding Lost

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

Main menu